$TONIX PHARMACEUTICALS HLDG C(TNXP)$ 明年是值得期待的一年。 1. 1Q2016 TNX-201 for Episodic Tension-Type Headache, Phase2 top-line data; 2. 2Q2016 TNX-102 SL for Post-Traumatic Stress Disorder, Phase 2 "AtEase" Study top-line data  3. 3Q2016 Phase 3 "AFFIRM" Study top-line data; 2Q2016, initial another phase 3 trial。 内部买入($7.5)